跳至主要内容
临床试验/NCT03318497
NCT03318497已完成2 期

Initial Evaluation of Role of Early Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

University of Texas Southwestern Medical Center1 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2017年12月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
6
试验地点
1
主要终点
Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of Chemotherapy

研究概览

简要总结

To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict overall survival at 1 and 2 years and progression free survival at 6 months and 1 year in patients with borderline resectable or locally advanced, pancreatic adenocarcinoma.

详细描述

The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.

Visit 1: Patients will have at least one visit with investigator (or investigator designee) prior to the study to review clinical history and prior treatment of pancreatic adenocarcinoma, and to explain the study. Correlative radiology studies including CT, MRI and 18F FDG-PET/CT as per institutional routine clinical care, and any clinically-directed laboratory tests performed as part of staging must be performed within 30 days of the 18F FLT-PET/CT

Visit 2 (Optional): The 18F-FDG-PET/CT may be done as a research scan, if the patient is unable to obtain a clinically-directed 18F-FDG-PET/CT as part of their clinical care or within 30 days of 18F FLT-PET/CT. The research 18F-FDG-PET/CT, in this instance, will be identical in procedure to the institution's clinical 18F-FDG-PET/CT. The blood glucose level will be < 200 mg/dl, before 18F-FDG injection, which is institutional standard clinical protocol. The following additional patient data will be obtained: histological diagnosis of primary and/or metastatic disease, date of diagnosis of primary and metastatic disease, gender, height, weight (for BMI), ECOG score and confirmation of absence of prior treatment.

Visit 3: Day of 18F-FLT-PET/CT: The patient will have an intravenous line placed in the hand or arm, 18F-FLT-PET/CT will be given by 1-2 minute IV push, and the dose administered will be approximately 5 mCi (+/- 20% dose). After approximately 60 +/- 10 minutes of uptake time, the patient will be positioned supine in the PET/CT scanner for standard whole body PET/CT scan from the skull base to mid-thigh. This scan will take approximately 20-30 min. The window from FLT PET/CT baseline study to initiation of chemotherapy should be no more than 30 days.

Visit 4: Day of Interim 18F-FLT-PET/CT: The interim 18F FLT-PET/CT will be performed after the 2nd cycle of chemotherapy regimen, but before the commencement of 3rd cycle. The second 18F-FLT-PET/CT study must be performed on the same scanner as the first 18F FLT-PET/CT and the imaging protocol described in Visit 3 should be closely followed.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with histologically confirmed pancreatic adenocarcinoma (resectable, borderline resectable or locally advanced disease at presentation) are eligible for the study.
  • Patients should not have any type of curative or palliative therapy for pancreatic adenocarcinoma before enrolling in the study.
  • Patients must be over 18 years old and capable and willing to provide informed consent.
  • Patients must have measurable disease (by RECIST 1.1 criteria)
  • Patients must have an ECOG performance status of 0-3 (restricted to ECOG PS 0-2 if age >70 years).
  • Patients of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to FLT (or FDG if for research) PET/CT imaging per institution's standard of care; A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria; Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
  • Medically stable as judged by patient's physician.
  • Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals of similar chemical or biologic composition to FLT are NOT eligible.
  • Ability to understand and the willingness to sign a written informed consent.
  • Patient must be able to lie still for a 20 to 30 minute PET/CT scan.

排除标准

  • Subjects who had prior chemotherapy or radiotherapy for pancreatic adenocarcinoma cannot participate in the study.
  • Patient must NOT be pregnant or breast-feeding.
  • Patients have no clinical evidence of distant metastatic disease
  • Patients must not weigh more than the maximum weight limit for the table for the PET/CT scanner where the study is being performed.(>200kg or 440lbs)

研究组 & 干预措施

Diagnostic (Interim FLT PET/CT)

Experimental

The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.

  • Procedure: Computed Tomography
  • Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
  • Other: Laboratory Biomarker Analysis
  • Procedure: Positron Emission Tomography

干预措施: Computed Tomography (Procedure)

Diagnostic (Interim FLT PET/CT)

Experimental

The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.

  • Procedure: Computed Tomography
  • Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
  • Other: Laboratory Biomarker Analysis
  • Procedure: Positron Emission Tomography

干预措施: Positron Emission Tomography (Procedure)

Diagnostic (Interim FLT PET/CT)

Experimental

The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.

  • Procedure: Computed Tomography
  • Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
  • Other: Laboratory Biomarker Analysis
  • Procedure: Positron Emission Tomography

干预措施: Laboratory Biomarker Analysis (Other)

结局指标

主要结局

Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of Chemotherapy

时间窗: Baseline(pre-treatment), 2 cycles after starting chemotherapy (each cycle 14 days)

Change in FLT PET/CT SUV Max after 2 cycles of chemotherapy will be compared to baseline (pre-treatment FLT PET/CT SUV Max)

Change From Baseline in SUV Peak of Lesion After 2 Cycles of Chemotherapy

时间窗: Baseline(pre-treatment), 2 cycles after starting chemotherapy (each cycle 14 days)

Change in FLT PET/CT SUV peak after 2 cycles of chemotherapy will be compared to baseline (pre-treatment FLT PET/CT SUV Peak)

2 Year Overall Survival

时间窗: Baseline(pre-treatment), until date of first observed death, assessed up to 2 years

Proportion of subjects who were alive at 2 years post-treatment is assessed

Change From Baseline in Proliferative Tumor Volume After 2 Cycles Chemotherapy

时间窗: Baseline(pre-treatment), 2 cycles after starting chemotherapy (each cycle 14 days)

Change in FLT PET/CT Proliferative tumor volume after 2 cycles of chemotherapy (compared to pre-treatment FLT PET/CT proliferative tumor volume)

1 Year Overall Survival

时间窗: Baseline(pre-treatment), until date of first observed death, assessed up to 1 year

Proportion of subjects who were alive at 1 year post-treatment is assessed

次要结局

  • 6 Months Progression Free Survival(Baseline (pre-treatment), until date of first observed progression, assessed up to 6 months)
  • 1 Year Progression Free Survival(Baseline(pre-treatment), until date of first observed progression, assessed up to 1 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Daniella Pinho

Assistant Professor, Radiology

University of Texas Southwestern Medical Center

研究点 (1)

Loading locations...

相似试验